Chordate Medical Holding AB (CMH) - Net Assets
Based on the latest financial reports, Chordate Medical Holding AB (CMH) has net assets worth Skr13.90 Million SEK (≈ $1.50 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr18.04 Million ≈ $1.94 Million USD) and total liabilities (Skr4.14 Million ≈ $445.82K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Chordate Medical Holding AB to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr13.90 Million |
| % of Total Assets | 77.04% |
| Annual Growth Rate | -13.99% |
| 5-Year Change | -64.14% |
| 10-Year Change | N/A |
| Growth Volatility | 59.34 |
Chordate Medical Holding AB - Net Assets Trend (2015–2024)
This chart illustrates how Chordate Medical Holding AB's net assets have evolved over time, based on quarterly financial data. Also explore Chordate Medical Holding AB assets under control for the complete picture of this company's asset base.
Annual Net Assets for Chordate Medical Holding AB (2015–2024)
The table below shows the annual net assets of Chordate Medical Holding AB from 2015 to 2024. For live valuation and market cap data, see CMH stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr9.20 Million ≈ $989.55K |
-39.05% |
| 2023-12-31 | Skr15.09 Million ≈ $1.62 Million |
+36.25% |
| 2022-12-31 | Skr11.07 Million ≈ $1.19 Million |
-71.57% |
| 2021-12-31 | Skr38.95 Million ≈ $4.19 Million |
+51.91% |
| 2020-12-31 | Skr25.64 Million ≈ $2.76 Million |
+133.51% |
| 2019-12-31 | Skr10.98 Million ≈ $1.18 Million |
-2.52% |
| 2018-12-31 | Skr11.26 Million ≈ $1.21 Million |
-38.24% |
| 2017-12-31 | Skr18.24 Million ≈ $1.96 Million |
-38.27% |
| 2016-12-31 | Skr29.55 Million ≈ $3.18 Million |
-17.29% |
| 2015-12-31 | Skr35.72 Million ≈ $3.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Chordate Medical Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1111192700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.08 Million | 120.55% |
| Other Components | Skr25.36 Million | 275.84% |
| Total Equity | Skr9.20 Million | 100.00% |
Chordate Medical Holding AB Competitors by Market Cap
The table below lists competitors of Chordate Medical Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Electricity Generating Public Company Limited
F:ECGF
|
$29.10K |
|
Ukrproduct Group
LSE:UKR
|
$30.05K |
|
XLMedia PLC
LSE:XLM
|
$30.17K |
|
WISHBONE GOLD PLC LS-001
F:7N6
|
$30.23K |
|
Anemoi International Ltd
LSE:AMOI
|
$28.66K |
|
Unicorn Mineral Resources PLC
LSE:UMR
|
$28.58K |
|
Premier African Minerals Ltd
LSE:PREM
|
$28.09K |
|
Sonder Holdings Inc
NASDAQ:SOND
|
$27.95K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Chordate Medical Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 15,086,539 to 9,195,162, a change of -5,891,377 (-39.1%).
- Net loss of 27,253,583 reduced equity.
- New share issuances of 21,362,207 increased equity.
- Other comprehensive income increased equity by 287,500,313.
- Other factors decreased equity by 287,500,314.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-27.25 Million | -296.39% |
| Share Issuances | Skr21.36 Million | +232.32% |
| Other Comprehensive Income | Skr287.50 Million | +3126.65% |
| Other Changes | Skr-287.50 Million | -3126.65% |
| Total Change | Skr- | -39.05% |
Book Value vs Market Value Analysis
This analysis compares Chordate Medical Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | Skr4.04 | Skr0.10 | x |
| 2016-12-31 | Skr3.34 | Skr0.10 | x |
| 2017-12-31 | Skr1776.61 | Skr0.10 | x |
| 2018-12-31 | Skr409.00 | Skr0.10 | x |
| 2019-12-31 | Skr144.77 | Skr0.10 | x |
| 2020-12-31 | Skr134.01 | Skr0.10 | x |
| 2021-12-31 | Skr0.25 | Skr0.10 | x |
| 2022-12-31 | Skr25.77 | Skr0.10 | x |
| 2023-12-31 | Skr23.45 | Skr0.10 | x |
| 2024-12-31 | Skr8.97 | Skr0.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Chordate Medical Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -296.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4100.21%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.91x
- Recent ROE (-296.39%) is below the historical average (-155.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -45.19% | -2502.02% | 0.01x | 1.33x | Skr-19.71 Million |
| 2016 | -46.39% | -8261.84% | 0.00x | 1.39x | Skr-16.66 Million |
| 2017 | -128.06% | -2346.57% | 0.03x | 1.60x | Skr-25.18 Million |
| 2018 | -236.91% | -2823.52% | 0.04x | 1.88x | Skr-27.81 Million |
| 2019 | -226.67% | -2138.75% | 0.06x | 1.72x | Skr-25.99 Million |
| 2020 | -77.06% | -3197.19% | 0.02x | 1.22x | Skr-22.32 Million |
| 2021 | -55.88% | -2467.70% | 0.02x | 1.13x | Skr-25.66 Million |
| 2022 | -252.36% | -25749.85% | 0.01x | 1.68x | Skr-29.05 Million |
| 2023 | -193.46% | -2989.58% | 0.04x | 1.46x | Skr-30.70 Million |
| 2024 | -296.39% | -4100.21% | 0.04x | 1.91x | Skr-28.17 Million |
Industry Comparison
This section compares Chordate Medical Holding AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $187,781,557
- Average return on equity (ROE) among peers: -22.45%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Chordate Medical Holding AB (CMH) | Skr13.90 Million | -45.19% | 0.30x | $29.05K |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $331.97K |
About Chordate Medical Holding AB
Chordate Medical Holding AB (publ), a medical technology company, engages in the development of products and solutions for neurostimulation treatment in Sweden. It offers Ozilia, a neuromodulation and medication-free treatment technology for chronic migraine and chronic rhinitis. The company was founded in 2005 and is based in Kista, Sweden.